Startups
DeepCyte combines single cell metabolomics with AI models to detect drug toxicity early. Reveal why cells turn toxic before drugs reach patients.
Mentions in press and media 3
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Apr 13, 2026 | DeepCyte Raises $1.5M in Seed Funding | DeepCyte, a Wilmington, DE-, and Copenhagen, Denmark-based techbio company building AI toxicology tools for drug development, raised $1.5M in Seed funding. The round was supported by Carl J. G. Evertsz. The company intends to use the funds ... |
| DeepCyte | “DeepCyte combines single cell metabolomics with AI models to detect drug toxicity early. Reveal why cells turn toxic before drugs reach patients.” |
Reviews 0
FAQ about DeepCyte
What has the press written about DeepCyte?
Parsers VC has collected 3 articles mentioning DeepCyte, among them “DeepCyte Raises $1.5M in Seed Funding” (Apr 13, 2026) and “DeepCyte”.
Is DeepCyte still active?
Yes, DeepCyte is active; its latest activity on Parsers VC dates from Apr 14, 2026.